Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

FDA reprimands Mylan for shoddy quality control at a key plant

  • Ed Silverman

By Ed Silverman July 2, 2018

Reprints
Mylan
Jeff Swensen/Getty Images

Several weeks ago, Mylan (MYL) unexpectedly disclosed plans to lay off more than 400 employees at a West Virginia manufacturing plant because the facility needed to be “right-sized and less complex.”

Now we know why.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

Texas judge strikes down major Obamacare provision protecting preventive…
Texas judge strikes down major Obamacare provision protecting preventive care
Former J&J exec, an in-demand free agent, takes the…
Former J&J exec, an in-demand free agent, takes the helm at privately held FogPharma
FDA proposes a new plan to streamline updates to…
FDA proposes a new plan to streamline updates to medical devices that use AI
Pharmalittle: FDA approves over-the-counter Narcan; J&J exits the race…
Pharmalittle: FDA approves over-the-counter Narcan; J&J exits the race for the first RSV vaccine
Former J&J exec, an in-demand free agent, takes the…
Former J&J exec, an in-demand free agent, takes the helm at privately held FogPharma
Is there $21 billion left for Covid response, or…
Is there $21 billion left for Covid response, or $5 billion? The White House is using…

Recommended Stories